Amerimmune Announces Filing of New Patent Application.Business Editors & Health/Medical Writers WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Oct. 7, 2002 Amerimmune Pharmaceuticals, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :AMUN), announced that it has filed a patent application to protect the company's intellectual property for an investigational monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing to treat patients suffering from human immunodeficiency virus human immunodeficiency virus n. HIV. Human immunodeficiency virus (HIV) A transmissible retrovirus that causes AIDS in humans. (HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. ) and Acquired Immune Deficiency Syndrome Acquired immune deficiency syndrome (AIDS) A viral disease of humans caused by the human immunodeficiency virus (HIV), which attacks and compromises the body's immune system. (AIDS). The newly filed patent application, a result of the company's ongoing clinical research and development program, is believed to be important to the protection of the company's overall drug development program and its potential advantage to HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome patients. However, there can be no assurance that a patent will be granted or that, if granted, this patent will be effective in protecting the company's intellectual property. To maintain its competitive advantage, the company will refrain from presenting details until the findings are published by the U.S. Patent and Trademark Office. Amerimmune is aware that it will be difficult to continue the development of this product without an infusion of investor capital and/or building a relationship with a major partner already established in the field of HIV/AIDS drug development and is actively seeking such a collaborative partner. About Amerimmune Pharmaceuticals, Inc. Amerimmune is engaged in pharmaceutical research and development with the primary purpose of developing an investigational agent designed to protect the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. , especially in patients suffering from HIV/AIDS. Amerimmune's intellectual property involves a monoclonal antibody that blocks certain adhesion molecules on one of the disease-fighting cells of the immune system, thereby protecting the immune system from "killer-type" T cells T cells A type of white blood cell produced in the thymus gland. T cells are an important part of the immune system. Infants born with an underdeveloped or absent thymus do not have a normal level of T cells in their blood. that tend to turn the human immune system against itself. By helping to shore up the immune system's natural defenses, this is a distinctly different therapeutic approach from antiviral drugs Antiviral Drugs Definition Antiviral drugs are medicines that cure or control virus infections. Purpose Antivirals are used to treat infections caused by viruses. (e.g., reverse transcriptase inhibitors and protease inhibitors Protease Inhibitors Definition A protease inhibitor is a type of drug that cripples the enzyme protease. An enzyme is a substance that triggers chemical reactions in the body. ), which take the offensive against the virus. The company believes that this may be an important drug for the growing number of patients who have not been receiving treatment and for those who are on multi-drug therapy but have become resistant or intolerant to drugs currently used to treat HIV/AIDS. For more information, please visit the company's Web site, www.amerimmune.com. Statements made in this news release that are not historical facts, such as the preliminary results of clinical trials, may constitute "forward-looking statements," which are made pursuant to the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions in the federal securities laws. Forward-looking statements are subject to risks, uncertainties and other factors beyond the control of the company that could cause actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. Factors that could cause actual results to differ materially from the company's expectations are detailed in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-KSB but include: (i) the uncertain and unpredictable results of both preliminary and large-scale clinical trials, including the possibility that later clinical trials will contradict or not support the results of the company's Phase 1 human clinical trials, (ii) the difficulties of obtaining FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals and the costs and other difficulties of complying with applicable regulatory restrictions even if such approvals can be obtained, (iii) the company's lack of operating history and financial resources, (iv) uncertainty as to the effectiveness of the company's protections of the intellectual property owned or licensed by it as well as the possibility of claims or challenges to the company's rights to critical intellectual property or technology, (v) the unavailability of sources of financing for the company's operations, (vi) competition within the pharmaceutical industry, (vii) the rapidly changing nature of technology and treatment methodology within the pharmaceutical and medical industries, and (viii) acceptance of any products developed by the company by medical professionals, medical insurers and others. The company disclaims any obligation to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion